In the United States, the Ear, Nose, and Throat (ENT) field sees 6 to 8 million sinus infections annually that escalate to chronic or severe stages requiring surgical intervention.
Presently, ENT surgeons face significant challenges in diagnosing common pathologies like sinus and ear infections, as well as those affecting the larynx and lungs. They often navigate this intricate anatomy blind, lacking visual guidance, or resort to using large and costly radiological systems that are neither convenient nor widely affordable.
The preferred solution for doctors is an optical device that offers easy navigation to specific anatomical destinations and provides high-quality direct visual imaging. However, existing steerable/flexible endoscopes have been limited by their large diameter, restricting access to certain anatomical areas. Moreover, their high cost makes them unsuitable for low-budget procedures, leading to questionable cleaning and reuse practices.
ENTnano Corp, a subsidiary of Luminus Holdings, is revolutionizing this landscape by offering doctors the first user-friendly, comprehensive visualization of sinus canals.
With this technology, doctors can:
Precisely measure and sample pathologies not clearly confirmed by CT or MRI scans.
Dilate constricted canals or openings to facilitate drainage and further inspection.
Relieve or remove pathologies causing inflammation and pressure.
Remove obstructive tumors or foreign bodies.
Precisely medicate at the site of infection, minimizing systemic exposure to antibiotics or other agents.
LuminusMicro executives have established strong relationships with over two dozen top surgical practices and universities eager to endorse and adopt ENTnano devices. Collectively, these partners perform over 2% of sinus infection procedures in the US market annually, translating to 120,000 to 160,000 procedures.
With nearly a 50% treatment failure rate, the ENT market demands better tools & techniques. ENTnano devices offer the definitive solution with enticing cost structures, and seamless integration into any medical practice.
ENTnano’s business strategy includes expanding production to meet current partner needs and exploring merger or acquisition opportunities with established global ENT device companies.
